Aurigene Oncology

Name

Aurigene Oncology

Legal name

Aurigene Discovery Technologies Limited

Website

https://aurigene.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Oncology Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Oncology drug discovery
• Small molecule therapeutics
• Targeted protein degradation
• Immuno-oncology
• Cancer therapeutics

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Aurigene out-licenses proprietary programs to global pharma and biotech companies. Revenue is generated through upfront payments, clinical development and regulatory milestones, commercial milestones, and royalties on net sales. Example: Olema deal included $8M upfront, up to $60M in clinical/regulatory milestones, up to $370M in commercial milestones, plus mid-single to low double digit royalties.
2. Co-development and Collaborative Research: Multi-year multi-program partnerships where Aurigene leads discovery and preclinical development while partners fund and lead clinical development, manufacturing, regulatory, and commercialization. Example: EQRx multi-program partnership for oncology and immune-inflammatory diseases with shared funding and financials from commercialization.
3. Self-sustaining Operations (Non-dilutive Revenue): Capital-efficient operating model with India-based infrastructure enabling faster and cost-effective R&D. Self-sustainable operations provide non-dilutive, recurring revenue. The company has achieved breakeven in past (per milestones page).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Aurigene Oncology is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule and cell therapy oncology drug candidates using proprietary platforms including targeted protein degradation (A-PROX), small molecule immuno-oncology, kinase inhibition, peptides, antibody engineering, and AI/ML for drug discovery. The company monetizes its pipeline primarily by licensing drug candidates to global pharmaceutical and biotechnology partners through upfront payments, development/commercial milestones, and royalties, while also conducting proprietary clinical development in India and partnering with government bodies like ICMR.

Product overview

Aurigene Oncology is a clinical-stage biopharmaceutical company with a diversified portfolio of novel cancer therapeutics spanning multiple modalities. The core portfolio includes small molecule programs (Cenopodlin, AUR103-AUR112) targeting immune checkpoints (VISTA, CD47, TIGIT), epigenetic targets (CBP/p300, PRMT5, RORgt), kinases (DDR1/SIK2, IRAK4), and enzymes (DHODH, MALT1), as well as cell therapy (Ribrecabtagene autoleucel CAR-T). These are supported by technology platforms including A-PROX for targeted protein degradation, an AI/ML platform for drug discovery acceleration, directed neo-substrate degrader platform, small molecule IO platform, kinase inhibitor platform, peptides platform, and antibody engineering platform. The company operates from Bangalore, India with GMP manufacturing capabilities including a CAR-T facility.

Differentiator

Problem solved

Functional benefit

Products and services

• Cenopodlin (AUR102 / CA-170)
• AUR103
• AUR104
• AUR105
• AUR106
• AUR107
• AUR108
• AUR109
• AUR101
• AUR110
• AUR112
• Ribrecabtagene autoleucel (DRL-1801)

Quantifiable outcome

• 63.6% overall response rate in efficacy-evaluable patients for AUR112 in relapsed/refractory lymphoid malignancies (Phase 1)
• +4 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

14 partnerships are on record, tiered minor and core.

• EdityminorStrategic or Co-development Partner · 17 April 2026Aurigene to provide cell therapy discovery services to Edity to support clinical development. Aurigene's CAR-T GMP manufacturing facility and cell therapy expertise are leveraged for Edity's programs.
• Indian Council of Medical Research (ICMR)coreStrategic or Co-development Partner · 14 September 2024MoA under ICMR's Network of Phase 1 Clinical Trials. Collaborative research over a small molecule for multiple myeloma. Marks pivotal step towards establishing India's self-sufficiency in clinical development. ICMR Network comprises KEMH & GSMC Mumbai, ACTREC Navi Mumbai, SRM MCH&RC Kattankulathur, and PGIMER Chandigarh, supported by a Central Coordinating Unit at ICMR HQ New Delhi.
• EQRxcoreStrategic or Co-development Partner · 5 July 2022Multi-program drug discovery, development, and commercialization partnership covering oncology and immune-inflammatory diseases. Aurigene leads discovery and preclinical development; EQRx assumes clinical development, manufacturing, regulatory, and commercialization. Parties share funding and commercialization financials. Validates Aurigene's discovery platform and moves the company into building a global oncology franchise.
• Olema OncologycoreStrategic or Co-development Partner · 9 June 2022Exclusive global license agreement to research, develop, and commercialize novel small molecule inhibitors of an undisclosed oncology target. $8M upfront, up to $60M in clinical/regulatory milestones, up to $370M in commercial milestones, plus mid-single to low double digit royalties on net sales. Olema leads clinical development and commercialization; Aurigene contributed pre-existing program.
• CuriscoreStrategic or Co-development Partner · 1 January 2015Multi-program licensing agreement. IRAK4 inhibitor CA-4948 (emavusertib) licensed to Curis for global development in hematologic malignancies. Aurigene retains certain rights.
• NovartiscoreStrategic or Co-development PartnerMulti-year, multi-target strategic partnerships for drug discovery. A candidate from the Novartis collaboration entered Phase 1.
• JanssencoreStrategic or Co-development PartnerMulti-year, multi-target strategic partnerships for drug discovery.
• ExelixiscoreStrategic or Co-development PartnerMulti-program licensing deal for developing drugs for oncology.
• AgioscoreStrategic or Co-development PartnerLicensing agreement with Agios for development of drug candidates.
• AstellascoreStrategic or Co-development PartnerLicensed programs including PPARδ modulators ASP0367 and ASP1128. Astellas acquired Mitobridge (formerly partnered with Aurigene).
• EisaicoreStrategic or Co-development PartnerFirst biotech partnership with H3 Biomedicine (subsidiary of Eisai). ESR1 ligand H3B-6545 in clinical development.
• Asana BiosciencesminorStrategic or Co-development PartnerLicensed SYK/JAK inhibitor ASN002 and BRAK/PI3K inhibitor ASN003 to Asana Biosciences.
• Orion PharmaminorStrategic or Co-development PartnerOption licensing deal with Orion Pharma for development of drug candidates.
• Mitobridge (Astellas)minorStrategic or Co-development PartnerPartnership with US biotech Mitobridge (currently an Astellas company) for development of PPARδ modulator programs.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Curis: Small US clinical-stage oncology company that licensed Aurigene's IRAK4 inhibitor (emavusertib/CA-4948). Operates a similar licensing-partnered model focused on hematologic malignancies, making it a directly comparable business model.
• Arvinas: US clinical-stage biotech pioneering targeted protein degradation (PROTAC platform) for oncology indications. Directly comparable to Aurigene's A-PROX platform in modality, target classes, and partnership-driven economics.
• Kymera Therapeutics: Clinical-stage degrader-focused biotech developing targeted protein degradation therapies in oncology and immunology. Overlapping technology platform (molecular glues/PROTACs) and similar early-clinical scaling dynamics make it a key direct peer.
• Nurix Therapeutics: Clinical-stage biotech developing small-molecule degrader therapies for oncology using ligase-directed chemistry. Comparable target-class breadth, partnership approach with large pharma, and degrader-platform focus.
• Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulation, including SMARCA2/4 and other SWI/SNF members. Highly comparable target overlap (SMARCA2 degraders) and oncology-discovery operating model.
• Olema Oncology: US clinical-stage oncology biotech with a licensing deal covering an undisclosed Aurigene-discovered target. Similar clinical-stage, partner-licensed business model and oncology focus.

Broad incumbents

• Exelixis: Established US oncology company with a multi-asset pipeline including kinase inhibitors and partnered programs with Aurigene. Larger and commercially active, but overlapping modality and partner-style deal flow.
• Agios Pharmaceuticals: Established oncology and rare-disease biotech that has licensed candidate programs from Aurigene. Comparable focus on small molecule oncology and partnership-driven development, but with deeper commercial footprint.

Regional players

• Jubilant Biosys: India-based integrated drug discovery CRO operating from Bangalore. Geographic and operational overlap with Aurigene's India-based discovery platform, though focused on services rather than proprietary clinical assets.

Others

• Syngene International: India-listed contract research organization offering discovery, development, and manufacturing services to global pharma. Plays an adjacent India-discovery ecosystem role alongside Aurigene's in-house capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/AurigeneDiscov
• LinkedInlinkedin.com/company/aurigene-discovery-technologies
• Facebookfacebook.com/aurigene-discovery-technologies-152736071453990

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurigene Oncology